HC Wainwright Reiterates “Buy” Rating for ArriVent BioPharma (NASDAQ:AVBP)

HC Wainwright reissued their buy rating on shares of ArriVent BioPharma (NASDAQ:AVBP) in a research note published on Friday morning,Benzinga reports. HC Wainwright currently has a $36.00 price objective on the stock.

AVBP has been the subject of a number of other research reports. Citigroup raised their target price on shares of ArriVent BioPharma from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Oppenheimer reiterated an “outperform” rating and set a $39.00 price objective (up previously from $35.00) on shares of ArriVent BioPharma in a research note on Tuesday, September 10th. Finally, The Goldman Sachs Group increased their target price on ArriVent BioPharma from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Tuesday, September 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $36.80.

ArriVent BioPharma Stock Down 0.6 %

NASDAQ:AVBP opened at $27.05 on Friday. ArriVent BioPharma has a 1-year low of $14.35 and a 1-year high of $36.37. The firm’s 50-day moving average price is $27.99 and its 200-day moving average price is $23.20.

Institutional Trading of ArriVent BioPharma

Institutional investors and hedge funds have recently modified their holdings of the business. Hhlr Advisors LTD. purchased a new stake in shares of ArriVent BioPharma during the 1st quarter valued at about $70,174,000. FMR LLC grew its position in ArriVent BioPharma by 8.7% in the 3rd quarter. FMR LLC now owns 2,119,695 shares of the company’s stock worth $49,813,000 after purchasing an additional 169,514 shares during the period. Suvretta Capital Management LLC raised its stake in ArriVent BioPharma by 7.7% during the 3rd quarter. Suvretta Capital Management LLC now owns 1,845,162 shares of the company’s stock valued at $43,361,000 after buying an additional 132,459 shares during the last quarter. Novo Holdings A S lifted its holdings in shares of ArriVent BioPharma by 0.4% during the 3rd quarter. Novo Holdings A S now owns 1,505,315 shares of the company’s stock valued at $35,375,000 after buying an additional 5,315 shares during the period. Finally, Vanguard Group Inc. purchased a new position in shares of ArriVent BioPharma in the 1st quarter worth $11,586,000. Institutional investors own 9.48% of the company’s stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.